Desk›Healthcare› Vivanza Biosciences Ltd
Vivanza Biosciences Ltd
BSE 530057 · NSE VIVANZA · ISIN INE984E01035 · Group X · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1.78
-2.20%
BSE close, 28 August 2026
₹7.12 cr
4.0 cr shares · Micro cap
₹5.69 cr
as published
13.7× · 1.44×
EPS ₹0.13 · BV ₹1.24
112.23 / 0.38
₹ cr, as filed
14
4 selected · 29%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -34.6% |
|---|---|
| Against 52-week low | +17.1% |
| Day change | -2.20% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹0.13 |
|---|---|
| Price / earnings | 13.69× |
| Price / book | 1.44× |
| Book value — derived, price ÷ P/B | ₹1.24 |
| Return on equity | 10.15% |
| Operating margin | 3.19% |
| Net margin | 1.59% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 10.52%
- ROE as published
- 10.15%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 9.14 | 0.15 | 0.04 | 3.19% | 1.59% |
| Mar-26 · Q | 5.75 | -0.27 | -0.07 | -0.80% | -4.63% |
| FY25-26 | 112.23 | 0.38 | 0.09 | 0.73% | 0.33% |
Quarter on quarter
- Revenue, quarter on quarter
- +59.0%
- Net profit, quarter on quarter
- +155.6%
- Operating margin, quarter on quarter
- +399 bps
Disclosure profile 14 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 2 |
| Results | 2 |
| Selected sub-total | 4 |
| Procedural | |
| Board Meeting | 3 |
| AGM / EGM | 2 |
| Annual Report | 1 |
| Compliance Certificate | 1 |
| General | 1 |
| Other Update | 1 |
| Trading Window | 1 |
| Procedural sub-total | 10 |
| Total | 14 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
14 filings · 4 selected · busiest 2026-08-07
Filing rhythm · the twelve most recent
2026-08-072026-10-08
SelectedProcedural
Filings
14 in the window · 9 earlier on record
-
8 October 2026 ·
Non Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI LODR Regulations, 2015
Non applicability of the statements of Variation and Deviation under regulation 32 of SEBI LODR Regulation, 2015 as Company has not raised any further funds, hence statements of Deviation ....
Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →
-
2 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance certificate under reg. 74(5) of SEBI (DP) Regulation 2018, received from Purva Share Registry (I) Pvt Ltd and Share Transfer Agent (RTA) of the company for the Quarter ended ....
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
28 September 2026 ·
Closure of Trading Window
Closure of Trading Window for the Quarter and half year ending 30th September, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
11 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of the 44th Annual General Meeting of the Members of the Vivanza Biosciences Limited.
AGM/EGM / AGM View filing →
-
20 August 2026 ·
Newspaper Publication
Please find enclosed newspaper advertisement w.r.t Notice of 44th AGM of the Company and e-voting information.
Company Update / General View filing →
-
19 August 2026 ·
Reg. 34 (1) Annual Report.
Annual Report for the Financial Year 2025-2026 of the Company.
Others / Reg. 34 (1) Annual Report View filing →
-
19 August 2026 ·
Notice Of The 44Th Annual General Meeting ('AGM') And Annual Report Of The Company For The Financial Year 2025-26
Notice of the 44th Annual General Meeting and Annual Report of the Company for the Financial Year 2025-26
AGM/EGM / AGM View filing →
-
17 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held On 17.08.2026
The Board of Directors of the Company at its meeting held on Monday, August 17, 2026, at the Registered Office, inter alia, considered and approved: 1. Director's Report, Secretarial Audit ....
Board Meeting / Outcome of Board Meeting View filing →
-
12 August 2026 ·
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1)(A) And Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Vivanza Biosciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve 1) To consider and approve ....
Board Meeting / Board Meeting View filing →
-
7 August 2026 ·
Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited ('The Company')
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 and other items .
Result / Financial Results View filing →
-
7 August 2026 ·
Outcome Of Board Of Directors Meeting Of Vivanza Biosciences Limited ('The Company')
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 and other items .
Result / Financial Results View filing →
-
7 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting To Consider And Approve Unaudited Financial Results (Standalone And Consolidated) For Quarter Ended 30Th June 2026
Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026, along with year-to-date figures for the period from 1st April, 2026, to 30th ....
Board Meeting / Outcome of Board Meeting View filing →
-
31 July 2026 ·
Update on board meeting
The Board Meeting to be held on 01/08/2026 has been revised to 07/08/2026 The Board Meeting to be held on 01/08/2026 has been revised to 07/08/2026
Company Update / Board Meeting Rescheduled View filing →
-
28 July 2026 ·
Board Meeting Intimation for The Consideration And Approval Of The Quarterly Financial Result Ended On 30Th June, 2026.
Vivanza Biosciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve 1. Unaudited Standalone ....
Board Meeting / Board Meeting View filing →
RSS feed for Vivanza Biosciences Ltd · the 50 most recent filings